China-origin assets accounted for an even larger share of big pharma licensing in Q1 2026
https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-biopharma-deck-q1-2026.pdf
-
https://s3.amazonaws.com/media.mediapost.com/uploads/DENTSU_GL1_February_2025.pdf
-
https://assets.contentstack.io/v3/assets/blt4eb669caa7dc65b2/blt79266ca5d3a390c1/Obesity_Drug_Market_Report.pdf
-
https://www.aranca.com/assets/docs/AI-Revolution-in-Drug-Industry-Transforming-R&D-and-Financial-Growth.pdf
